Premium
Intravenous magnesium sulfate in the management of severe pre‐eclampsia: A randomized study of 12‐hour versus 24‐hour maintenance dose
Author(s) -
Unwaha Emmanuel A.,
Bello Folasade A.,
Bello Oluwasomidoyin O.,
Oladokun Adesina
Publication year - 2020
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.13082
Subject(s) - medicine , eclampsia , randomized controlled trial , regimen , adverse effect , maintenance dose , obstetrics , loading dose , pregnancy , anesthesia , surgery , genetics , biology
Objective To assess the effectiveness of a 12‐hour versus 24‐hour intravenous maintenance dose of magnesium sulfate (Mg SO 4 ) in women with pre‐eclampsia, and the maternal and fetal outcomes. Methods This was a randomized controlled trial conducted at the labor ward complex of University College Hospital, Ibadan, Nigeria between May and August 2014. Pregnant women with severe pre‐eclampsia were randomized to receive a 12‐hour versus 24‐hour maintenance dose of Mg SO 4 . Study outcomes were occurrence of seizures, adverse maternal effects, neonatal survival, and admission to the intensive care unit. Data analysis involved descriptive statistics and bivariate analysis using Statistical Package for Social Science ( SPSS ) version 20. Results There were 80 patients randomized to the 12‐hour (n=40) and 24‐hour (n=40) groups. The participants in the two groups had comparable demographic features. There was no significant difference ( P >0.999) between the satisfactory maternal outcome following the 12‐hour maintenance dose and the standard 24‐hour regimen (95.0% vs 97.5%). Similarly, there was no significant difference ( P =0.276) in perinatal mortality in the 12‐hour versus 24‐hour arm (17.5% vs 12.5%, respectively). No case of eclampsia and maternal death was recorded. Conclusion A 12‐hour maintenance dose of intravenous Mg SO 4 in the management of severe pre‐eclampsia is effective and safe when compared with the 24‐hour maintenance dose.